Open AccessGenomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Author(s) -
Alexander W. Wyatt,
Arun Azad,
Stanislav Volik,
Matti Annala,
Kevin Beja,
Brian McConeghy,
Anne Haegert,
Evan W. Warner,
Fan Mo,
Sonal Brahmbhatt,
Robert Shukin,
Stéphane Le Bihan,
Martin Gleave,
Matti Nykter,
Colin C. Collins,
Kim N.
Publication year - 2016
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2016.0494
Subject(s) - enzalutamide , prostate cancer , medicine , interquartile range , oncology , cell free fetal dna , prostate specific antigen , cancer , androgen deprivation therapy , androgen receptor , biology , genetics , fetus , prenatal diagnosis , pregnancy
The molecular landscape underpinning response to the androgen receptor (AR) antagonist enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) is undefined. Consequently, there is an urgent need for practical biomarkers to guide therapy selection and elucidate resistance. Although tissue biopsies are impractical to perform routinely in the majority of patients with mCRPC, the analysis of plasma cell-free DNA (cfDNA) has recently emerged as a minimally invasive method to explore tumor characteristics.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom